UnknownNot Applicable

Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria

Denmark6 participantsStarted 2023-02-23

Plain-language summary

What is the visible light protective effect of dihydroxyacetone in individuals with erythropoietic protoporphyria? This will be tested in this randomized blinded placebo controlled study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with erythropoietic protoporphyria * At least 18 years of age * Obtainment of written informed consent Exclusion Criteria: * Pregnant or breastfeeding * Use of dihydroxyacetone at the treatment or placebo fields within the last two week * Sun exposure of the treatment or placebo fields within the last two week * Use of suncreen or other local treatment on the treatment or placebo fields during the study period (two days) * Allergy to adhesive bandages, dihydroxyacetone or lotion

What they're measuring

Visible light exposure dose to onset of first skin symptom

Timeframe: Meassurement one day after dihydroxyacetone application

Trial details

NCT IDNCT05780840

SponsorBispebjerg Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09

View on ClinicalTrials.gov More Erythropoietic Protoporphyria trials